|
|
Post by stockwhisperer on Jun 14, 2024 9:12:55 GMT -5
It’s just a moment in time - unless you are a trader.
|
|
|
|
Post by factspls88 on Jun 14, 2024 9:31:14 GMT -5
No respect tell ya. That said, there’s a nearly perfect reverse head and shoulders forming after the March run up. 🙏
|
|
|
|
Post by stella on Jun 14, 2024 9:50:52 GMT -5
This stock usually trades the same way most days, absent news. Light volume at the open takes it down. Buyers wait for the drop and then buy at lower levels. Why battle the sellers/shorts who are picking up pennies in front of a steamroller? Patience is a virtue.
|
|
|
|
Post by Chris-C on Jun 14, 2024 11:20:09 GMT -5
…and mine, speaking as one yuletide season conception baby to another. 😊This stock is so predictable it’s tempting to open a play account and cash in on the predictability. However, I think the day-trading enthusiasm for the stock will fade once it hits 10. |
|
|
|
Post by ktim on Jun 14, 2024 11:20:32 GMT -5
Well it only lasted less than a day. Back down below $5. It was exciting. As the scorpion said to the frog... it's in MNKD's nature. |
|
|
|
Post by Chris-C on Jun 14, 2024 13:31:14 GMT -5
Well it only lasted less than a day. Back down below $5. It was exciting. As the scorpion said to the frog... it's in MNKD's nature. Master: “Patience, Grasshopper. You must learn to hop before you can fly .” Grasshopper: “Yes, Master. I understand. But Must I also learn to hop backward? Master: yes grasshopper, it is in your nature.” |
|
|
|
Post by neil36 on Aug 7, 2024 9:31:34 GMT -5
On the Yahoo! analysis page, the HIGH estimate for the next earnings report is $74.66 million. We essentially did that this quarter. Upward revisions should be coming in the near future.
|
|
|
|
Post by neil36 on Aug 7, 2024 17:08:03 GMT -5
If we stayed flat, our revenue for 2025 would be $288 million. The HIGH Yahoo! analyst revenue exstimate for 2025 is $290 million.
I'm ignoring the GAAP loss, focused on the non-GAAP huge beat, the debt paydown that caused the GAAP miss, and the huge revenue beat, and the growth trendline that is getting clearer and clearer.
|
|
|
|
Post by prcgorman2 on Aug 8, 2024 15:06:10 GMT -5
Speaking of paying off debt and a strictly GAAP lens, I can't wait for the quarter MannKind pays off the $230M in convertible bonds. It should be ugly on the books in the quarter it is retired, and beautiful on the books afterwards. Will the market kill or be kind to MNKD when the debt is paid? I expect the SIR to diminish to "average" levels. And then maybe we'll see DIVIDENDS. Can't believe I just wrote that. (If/when that happens, I'll be joining the dividend re-investment program ASAP - assuming I'm still alive.  ) |
|
|
|
Post by mayday on Aug 8, 2024 15:10:36 GMT -5
Speaking of paying off debt and a strictly GAAP lens, I can't wait for the quarter MannKind pays off the $230M in convertible bonds. It should be ugly on the books in the quarter it is retired, and beautiful on the books afterwards. Will the market kill or be kind to MNKD when the debt is paid? I expect the SIR to diminish to "average" levels. And then maybe we'll see DIVIDENDS. Can't believe I just wrote that. (If/when that happens, I'll be joining the dividend re-investment program ASAP - assuming I'm still alive. ) There's the Kicker! (Assuming we are still alive) ... |
|
|
|
Post by ktim on Aug 8, 2024 16:47:40 GMT -5
Or we could rely on MNKD themselves having a re-investment program into a robust pipeline, which is the more typical route for a biotech.
|
|
|
|
Post by prcgorman2 on Aug 8, 2024 17:03:46 GMT -5
The professor I had for "Corporate Finance" asserted all mature companies pay dividends, and pointed to tech giants that had resisted for years, but finally did. I think the important point is "mature" versus "growth". Growth and contraction (one way or the other) is a cycle in mature companies, thanks to the challenges mainly of maintaining consistently good management (I assert). But "young" companies provide value through growth. MannKind is anything but young, but they're unequivocally in the growth stage still. Someday, if all goes well, they'll be grown and mature, and then they'll either be inclined or feel they need to pay dividends. I found a study a few years ago that argued that companies which paid dividends fared better as compared to companies that didn't. I don't remember the measurement of success anymore, but it was interesting reading anyway.  |
|
|
|
Post by ktim on Aug 8, 2024 17:42:11 GMT -5
The professor I had for "Corporate Finance" asserted all mature companies pay dividends, and pointed to tech giants that had resisted for years, but finally did. I think the important point is "mature" versus "growth". Growth and contraction (one way or the other) is a cycle in mature companies, thanks to the challenges mainly of maintaining consistently good management (I assert). But "young" companies provide value through growth. MannKind is anything but young, but they're unequivocally in the growth stage still. Someday, if all goes well, they'll be grown and mature, and then they'll either be inclined or feel they need to pay dividends. I found a study a few years ago that argued that companies which paid dividends fared better as compared to companies that didn't. I don't remember the measurement of success anymore, but it was interesting reading anyway. That certainly is an interesting topic in general, and obviously varying opinions even among the cohort of very successful business leaders. Not that I have much finance training, other trial by fire, but... I think biotech, even large pharma to some extent, are never quite a "mature" company. Reason being that drugs always face patent cliffs, and health payment systems rightly aren't going to consider brand loyalty when it comes to a particular drug if highly regulated exact copies are available at much cheaper prices. Drug companies are thus highly dependent on a pipeline. Sometimes pipelines can be extensions of an existing drug more akin to the pipeline of developing new versions of an iPhone, but often the pipeline is made up of truly new products giving drug companies a characteristic of almost being a perpetual startup. They have to keep reinventing themselves through novel R&D or they are dead eventually. Many tech companies that don't pay dividends do so because they view the imperative to innovate in a similar manner, but arguably drug development is worse than tech in that regard. Personally I hope for years to come we're plowing our profits into broadening the pipeline... and of course that we have an above average shots on goal ratio. |
|
|
|
Post by prcgorman2 on Aug 9, 2024 7:35:04 GMT -5
I’m not sure what the restrictions are on drug developers getting into other lines of business, but you made the case for diversification. Prohibition strained a lot of beverage makers but several did successfully pivot, lasted through the Prohibition years, and then thrived. The only point being here that innovation aligned with current business can provide a source of revenue without the same risk/reward profile. I have to wonder whether we’ll see other UTHR pork products besides transplantable organs.
|
|
|
|
Post by Clement on Aug 9, 2024 7:46:49 GMT -5
AI pigs!
|
|
)